Results 11 to 20 of about 5,052,436 (221)
Case Reports in Nephrology, 2018 Renal artery thromboembolism (RATE) is an uncommon complication of renal arteries from heart chamber. Although there is no treatment protocol prescribed with guidelines, thrombolytic agents such as rt-PA are frequently used.
Ahmet Karakurt
doaj +2 more sources
Initial Results of Oral Thrombolytic Agent Clinical Application
Proceedings, 2018 At the moment, there is no oral thrombolytic drug on the world pharmaceutical market. The drug Trombovazim, which has a thrombolytic effect under oral administration, has been registered in Russia. It differs from all thrombolytics—it has a fundamentally
Pavel Madonov +5 more
doaj +2 more sources
CLINICAL CASE OF THROMBOLYTIC THERAPY OF RECURRENT ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION IN PATIENT WITH LONG HISTORY OF ISCHEMIC HEART DISEASE [PDF]
Рациональная фармакотерапия в кардиологии, 2016 Presented case report demonstrates the efficacy and safety of hospital use of thrombolytic agent Fortelizin in pharmaco-invasive strategy for the treatment of a patient with acute myocardial infarction and with a long history of ischemic heart disease ...
N. T. Vatutin +3 more
doaj +2 more sources
Update on Thrombolytic Therapy in Acute Pulmonary Thromboembolism.
Eurasian Journal of Medicine, 2019 Thrombolytic treatment accelerates the dissolution of thrombus in acute pulmonary thromboembolism (PTE) and is potentially a lifesaving treatment. High-risk PTE is the clearest indication for this therapy, and its use in intermediate-risk cases is still ...
E. Uçar
semanticscholar +2 more sources
CLINICAL RESULTS OF THROMBOLYTIC THERAPY WITH ALTEPLASE AND TENECTEPLASE IN PATIENTS WITH MYOCARDIAL INFARCTION [PDF]
Рациональная фармакотерапия в кардиологии, 2015 Aim. To evaluate the clinical results of thrombolytic therapy with thrombolytics (alteplase, tenecteplase) in patients with ST segment elevation myocardial infarction (STEMI). Material and methods.
L. A. Bondarenko +4 more
doaj +4 more sources
Clinical trial of fibrinselective thrombolytic pharmaceutical agent «FORTELYZIN®» (III Phase)
RUDN Journal of Medicine, 2012 The clinical trial of fibrinselective thrombolytic agent Fortelyzin® (III phase) showed the comparative efficacy and safety with Actilyse® in patients with acute myocardial infarction and obtained data permitted to recommend it for clinical usage.
S S Markin +5 more
doaj +1 more source
Indonesian Journal of Biotechnology, 2023 Thrombolytic agents are used for thrombolytic therapy to dissolve blood clots that form in a blood vessel. All currently used thrombolytic agents have unfavorable shortcomings, such as gastrointestinal bleeding, allergic reactions, and thrombolytic agent
Urbanus Yustus Lebuan +3 more
doaj +2 more sources
Tenecteplase Thrombolysis in Posterior Circulation Stroke
Frontiers in Neurology, 2021 One in five ischaemic strokes affects the posterior circulation. Basilar artery occlusion is a type of posterior circulation stroke associated with a high risk of disability and mortality.
Fana Alemseged, Bruce C. V. Campbell
doaj +1 more source
Assessing Safety of Thrombolytic Therapy [PDF]
Seminars in Thrombosis and Hemostasis, 2016 Thrombolytic therapy involves thrombolytic agents administered to patients suffering from venous or arterial thrombosis. The therapy induces systemic effects interrelated with the thrombolytic agent used.
C. Kluft, J. Sidelmann, J. Gram
semanticscholar +2 more sources
Histomorphometric analysis of the lung of Swiss mice treated with a fibrinolytic protease
Anais da Academia Brasileira de Ciências, 2022 Fibrinolytic enzymes are considered promising alternative in the treatment of cardiovascular diseases by preventing fibrin clots. A protease from Mucor subtilissimus UCP 1262 was obtained by solid state fermentation and purified by ion exchange ...
MARLLYN M. DA SILVA +10 more
doaj +1 more source